Saccharomyces cerevisiae genetics predicts candidate therapeutic genetic interactions at the mammalian replication fork

G3: Genes, Genomes, Genetics

Volumn 3, Issue 2, 2013, Pages 273-282

  van Pel, Derek M ^a   Stirling, Peter C ^a   Minaker, Sean W ^a   Sipahimalani, Payal ^a   Hieter, Philip ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Cancer therapy; Chromosome; DNA replication; Instability.; Synthetic lethality; Yeast genomics

Indexed keywords

SMALL INTERFERING RNA; CTF4 PROTEIN, S CEREVISIAE; DNA BINDING PROTEIN; MRE11A PROTEIN, HUMAN; MUTAGENIC AGENT; SACCHAROMYCES CEREVISIAE PROTEIN;

ARTICLE; CANCER CELL; CHROMOSOMAL INSTABILITY; COLORECTAL CANCER CELL LINE; CTF4 GENE; DNA REPLICATION; ENZYME ACTIVITY; ESSENTIAL GENE; FUNGAL GENE; FUNGAL GENETICS; GENE INTERACTION; HUMAN; HUMAN CELL; MAMMAL CELL; MRE11A GENE; PREDICTION; SACCHAROMYCES CEREVISIAE; SOMATIC MUTATION; TUMOR GENE; CANCER THERAPY; CELL STRAIN HCT116; COLORECTAL TUMOR; DRUG ANTAGONISM; DRUG EFFECT; FUNGAL GENOME; GENE REGULATORY NETWORK; GENETICS; METABOLISM; MUTATION; RNA INTERFERENCE; SYNTHETIC LETHALITY; YEAST GENOMICS;

EUKARYOTA; MAMMALIA; SACCHAROMYCES CEREVISIAE;

CANCER THERAPY; CHROMOSOME INSTABILITY; DNA REPLICATION; SYNTHETIC LETHALITY; YEAST GENOMICS;

CHROMOSOMAL INSTABILITY; COLORECTAL NEOPLASMS; DNA REPLICATION; DNA-BINDING PROTEINS; GENE REGULATORY NETWORKS; GENES, ESSENTIAL; GENOME, FUNGAL; HCT116 CELLS; HUMANS; MUTAGENS; MUTATION; RNA INTERFERENCE; RNA, SMALL INTERFERING; SACCHAROMYCES CEREVISIAE; SACCHAROMYCES CEREVISIAE PROTEINS;

EID: 84883182565     PISSN: None     EISSN: 21601836     Source Type: Journal    
DOI: 10.1534/g3.112.004754     Document Type: Article

References (54)

1. Balgi, A.D., and M. Roberge, 2009 Screening for chemical inhibitors of heterologous proteins expressed in yeast using a simple growth-restoration assay. Methods Mol. Biol. 486: 125-137.
2. Barretina, J., G. Caponigro, N. Stransky, K. Venkatesan, A. A. Margolin et al., 2012 The cancer cell line encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 483: 603-607.
3. Baryshnikova, A., M. Costanzo, S. Dixon, F. J. Vizeacoumar, C. L. Myers et al., 2010 Synthetic genetic array (SGA) analysis in Saccharomyces cerevisiae and Schizosaccharomyces pombe. Methods Enzymol. 470: 145-179.
4. Ben-Aroya, S., C. Coombes, T. Kwok, K. A. O'Donnell, J. D. Boeke et al., 2008 Toward a comprehensive temperature-sensitive mutant repository of the essential genes of Saccharomyces cerevisiae. Mol. Cell 30: 248-258.
5. Biggins, S., N. Bhalla, A. Chang, D. L. Smith, and A. W. Murray, 2001 Genes involved in sister chromatid separation and segregation in the budding yeast Saccharomyces cerevisiae. Genetics 159: 453-470.
6. Birkbak, N. J., A. C. Eklund, Q. Li, S. E. McClelland, D. Endesfelder et al., 2011 Paradoxical relationship between chromosomal instability and survival outcome in cancer. Cancer Res. 71: 3447-3452.
7. Brenner, J. C., F. Y. Feng, S. Han, S. Patel, S. V. Goyal et al., 2012 PARP-1 inhibition as a targeted strategy to treat ewing's sarcoma. Cancer Res. 72: 1608-1613.
8. Breslow, D. K., D. M. Cameron, S. R. Collins, M. Schuldiner, J. Stewart-Ornstein et al., 2008 A comprehensive strategy enabling high-resolution functional analysis of the yeast genome. Nat. Methods 5: 711-718.
9. Brough, R., J. R. Frankum, S. Costa-Cabral, C. J. Lord, and A. Ashworth, 2011 Searching for synthetic lethality in cancer. Curr. Opin. Genet. Dev. 21: 34-41.
10. Bryant, H. E., N. Schultz, H. D. Thomas, K. M. Parker, D. Flower et al., 2005 Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 434: 913-917.
11. Burns, C. G., R. Ohi, S. Mehta, E. T. O'Toole, M. Winey et al., 2002 Removal of a single alpha-tubulin gene intron suppresses cell cycle arrest phenotypes of splicing factor mutations in saccharomyces cerevisiae. Mol. Cell. Biol. 22: 801-815.
12. Carroll, S. Y., P. C. Stirling, H. E. Stimpson, E. Giesselmann, M. J. Schmitt et al., 2009 A yeast killer toxin screen provides insights into a/b toxin entry, trafficking, and killing mechanisms. Dev. Cell 17: 552-560.
13. Collins, S. R., K. M. Miller, N. L. Maas, A. Roguev, J. Fillingham et al., 2007 Functional dissection of protein complexes involved in yeast chromosome biology using a genetic interaction map. Nature 446: 806-810.
14. Costanzo, M., A. Baryshnikova, J. Bellay, Y. Kim, E. D. Spear et al., 2010 The genetic landscape of a cell. Science 327: 425-431.
15. Dupre, A., L. Boyer-Chatenet, R. M. Sattler, A. P. Modi, J. H. Lee et al., 2008 A forward chemical genetic screen reveals an inhibitor of the Mre11-Rad50-Nbs1 complex. Nat. Chem. Biol. 4: 119-125.
16. Farmer, H., N. McCabe, C. J. Lord, A. N. Tutt, D. A. Johnson et al., 2005 Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434: 917-921.
17. Futreal, P. A., L. Coin, M. Marshall, T. Down, T. Hubbard et al., 2004 A census of human cancer genes. Nat. Rev. Cancer 4: 177-183.
18. Garnett, M. J., E. J. Edelman, S. J. Heidorn, C. D. Greenman, A. Dastur et al., 2012 Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature 483: 570-575.
19. Giaever, G., A. M. Chu, L. Ni, C. Connelly, L. Riles et al., 2002 Functional profiling of the Saccharomyces cerevisiae genome. Nature 418: 387-391.
20. Giaever, G., P. Flaherty, J. Kumm, M. Proctor, C. Nislow et al., 2004 Chemogenomic profiling: identifying the functional interactions of small molecules in yeast. Proc. Natl. Acad. Sci. USA 101: 793-798.
21. Gordon, D. J., B. Resio, and D. Pellman, 2012 Causes and consequences of aneuploidy in cancer. Nat. Rev. Genet. 13: 189-203.
22. Hartwell, L. H., P. Szankasi, C. J. Roberts, A. W. Murray, and S. H. Friend, 1997 Integrating genetic approaches into the discovery of anticancer drugs. Science 278: 1064-1068.
23. Herrero, A. B., and S. Moreno, 2011 Lsm1 promotes genomic stability by controlling histone mRNA decay. EMBO J. 30: 2008-2018.
24. Hillenmeyer, M. E., E. Fung, J. Wildenhain, S. E. Pierce, S. Hoon et al., 2008 The chemical genomic portrait of yeast: Uncovering a phenotype for all genes. Science 320: 362-365.
25. Im, J. S., S. H. Ki, A. Farina, D. S. Jung, J. Hurwitz et al., 2009 Assembly of the Cdc45-Mcm2-7-GINS complex in human cells requires the Ctf4/And-1, RecQL4, and Mcm10 proteins. Proc. Natl. Acad. Sci. USA 106: 15628-15632.
26. Kaelin, W. G. Jr, 2005 The concept of synthetic lethality in the context of anticancer therapy. Nat. Rev. Cancer 5: 689-698.
27. Kim, E. M., and D. J. Burke, 2008 DNA damage activates the SAC in an ATM/ATR-dependent manner, independently of the kinetochore. PLoS Genet. 4: e1000015.
28. Koh, J. L., H. Ding, M. Costanzo, A. Baryshnikova, K. Toufighi et al., 2010 DRYGIN: a database of quantitative genetic interaction networks in yeast. Nucleic Acids Res. 38: D502-D507.
29. Li, Z., F. J. Vizeacoumar, S. Bahr, J. Li, J. Warringer et al., 2011 Systematic exploration of essential yeast gene function with temperature-sensitive mutants. Nat. Biotechnol. 29: 361-367.
30. Loeb, L. A., 2011 Human cancers express mutator phenotypes: origin, consequences and targeting. Nat. Rev. Cancer 11: 450-457.
31. Luo, J., M. J. Emanuele, D. Li, C. J. Creighton, M. R. Schlabach et al., 2009 A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the ras oncogene. Cell 137: 835-848.
32. McLellan, J. L., N. J. O'Neil, I. Barrett, E. Ferree, D. M. van Pel et al., 2012 Synthetic lethality of cohesins with PARPs and replication fork mediators. PLoS Genet. 8: e1002574.
33. McManus, K. J., I. J. Barrett, Y. Nouhi, and P. Hieter, 2009 Specific synthetic lethal killing of RAD54B-deficient human colorectal cancer cells by FEN1 silencing. Proc. Natl. Acad. Sci. USA 106: 3276-3281.
34. Mimura, S., T. Yamaguchi, S. Ishii, E. Noro, T. Katsura et al., 2010 Cul8/ Rtt101 forms a variety of protein complexes that regulate DNA damage response and transcriptional silencing. J. Biol. Chem. 285: 9858-9867.
35. Parsons, A. B., A. Lopez, I. E. Givoni, D. E. Williams, C. A. Gray et al., 2006 Exploring the mode-of-action of bioactive compounds by chemical-genetic profiling in yeast. Cell 126: 611-625.
36. Scholl, C., S. Frohling, I. F. Dunn, A. C. Schinzel, D. A. Barbie et al., 2009 Synthetic lethal interaction between oncogenic KRAS dependency and STK33 suppression in human cancer cells. Cell 137: 821-834.
37. Shannon, P., A. Markiel, O. Ozier, N. S. Baliga, J. T. Wang et al., 2003 Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 13: 2498-2504.
38. Smith, A. M., L. E. Heisler, J. Mellor, F. Kaper, M. J. Thompson et al., 2009 Quantitative phenotyping via deep barcode sequencing. Genome Res. 19: 1836-1842.
39. Spencer, F., S. L. Gerring, C. Connelly, and P. Hieter, 1990 Mitotic chromosome transmission fidelity mutants in saccharomyces cerevisiae. Genetics 124: 237-249.
40. Stirling, P. C., M. S. Bloom, T. Solanki-Patil, S. Smith, P. Sipahimalani et al., 2011 The complete spectrum of yeast chromosome instability genes identifies candidate CIN cancer genes and functional roles for ASTRA complex components. PLoS Genet. 7: e1002057.
41. Stirling, P. C., M. J. Crisp, M. A. Basrai, C. M. Tucker, M. J. Dunham et al., 2012a Mutability and mutational spectrum of chromosome transmission fidelity genes. Chromosoma 121: 263-275.
42. Stirling, P. C., Y. A. Chan, S. W. Minaker, M. J. Aristizabal, I. Barrett et al., 2012b R-loop-mediated genome instability in mRNA cleavage and polyadenylation mutants. Genes Dev. 26: 163-175.
43. Stratton, M. R., P. J. Campbell, and P. A. Futreal, 2009 The cancer genome. Nature 458: 719-724.
44. The Cancer Genome Atlas Research Network, 2012 Comprehensive genomic characterization of squamous cell lung cancers. Nature 489: 519-525.
45. Tkach, J. M., A. Yimit, A. Y. Lee, M. Riffle, M. Costanzo et al., 2012 Dissecting DNA damage response pathways by analysing protein localization and abundance changes during DNA replication stress. Nat. Cell Biol. 14: 966-976.
46. Tong, A. H., M. Evangelista, A. B. Parsons, H. Xu, G. D. Bader et al., 2001 Systematic genetic analysis with ordered arrays of yeast deletion mutants. Science 294: 2364-2368.
47. Tong, A. H., G. Lesage, G. D. Bader, H. Ding, H. Xu et al., 2004 Global mapping of the yeast genetic interaction network. Science 303: 808-813.
48. Torres, J. Z., S. L. Schnakenberg, and V. A. Zakian, 2004 Saccharomyces cerevisiae Rrm3p DNA helicase promotes genome integrity by preventing replication fork stalling: Viability of rrm3 cells requires the intra-S-phase checkpoint and fork restart activities. Mol. Cell. Biol. 24: 3198-3212.
49. van Pel, D.M., I. J. Barrett, Y. Shimizu, B.V. Sajesh, B. Guppy et al., 2013 An evolutionarily conserved synthetic lethal interaction network identifies FEN1 as a broad-spectrum target for anticancer therapeutic development. PLoS Genet. DOI: 10.1371/journal.pgen.1003254 (in press).
50. Vilar, E., C. M. Bartnik, S. L. Stenzel, L. Raskin, J. Ahn et al., 2011 MRE11 deficiency increases sensitivity to poly(ADP-ribose) polymerase inhibition in microsatellite unstable colorectal cancers. Cancer Res. 71: 2632-2642.
51. Weaver, B. A., and D. W. Cleveland, 2006 Does aneuploidy cause cancer? Curr. Opin. Cell Biol. 18: 658-667.
52. Williamson, C. T., H. Muzik, A. G. Turhan, A. Zamo, M. J. O'Connor et al., 2010 ATM deficiency sensitizes mantle cell lymphoma cells to poly (ADP-ribose) polymerase-1 inhibitors. Mol. Cancer Ther. 9: 347-357.
53. Yuen, K. W., C. D. Warren, O. Chen, T. Kwok, P. Hieter et al., 2007 Systematic genome instability screens in yeast and their potential relevance to cancer. Proc. Natl. Acad. Sci. USA 104: 3925-3930.
54. Zhu, W., C. Ukomadu, S. Jha, T. Senga, S. K. Dhar et al., 2007 Mcm10 and and-1/CTF4 recruit DNA polymerase alpha to chromatin for initiation of DNA replication. Genes Dev. 21: 2288-2299.